where checking accounts rebuild communities
Back to homepageInstitutional ReportsSRI Financial Professionals DirectoryToolsNewsSRI Performance and TrendsAbout Us   

July 21, 2004
Two Socially Responsible Investing Funds Generate Double-Digit Year-to-Date Returns
    by William Baue

The Ariel Fund and the Pax World Growth Fund perform well in the first half of this year.

Of the 60-odd socially responsible investment (SRI) mutual funds tracked by, two funds have produced year-to-date (YTD) returns in the double digits at the half-year mark. The Ariel Fund (ticker: ARGFX) generated YTD returns of 11.84 percent, placing it in the third percentile compared to its peers--domestic equity value funds that invest in small- and mid-cap companies. (In other words, it performed better than 97 percent of its peer funds.) The Pax World Growth Fund (PXWGX) produced YTD returns of 10.61 percent, ranking in the second percentile compared to its peers--domestic equity growth funds that invest in mid- and large-cap companies.

All performance statistics cited in this article are current as of June 30, 2004, and are based on data provided by Thomson Financial Network, unless otherwise noted.

On social issues, the two funds converge on some screens. Both funds exclude companies that produce weapons, nuclear power, tobacco, and negative impacts on the environment, and both have positive screens for strong employment policies. Neither fund practices community investment.

The funds diverge on other social issues. For example, the Pax World practices shareowner advocacy, engaging with companies it holds to encourage progressive social and environmental policies and practices; Ariel does not. The Pax World Growth Fund also employs several additional screens, such as exclusions on companies involved in alcohol and gambling. In contrast, the top holding in the Ariel Fund portfolio is Caesars Entertainment (ticker: CZR), a casino operator.

The top holding in the Pax World Growth Fund portfolio, Dick's Sporting Goods (DKS), does not particularly exemplify social responsibility, according to portfolio manager Paul Gulden, except that it is not involved in any of the controversial areas screened by SRI. Mr. Gulden attributes the strong recent performance of the fund in large part to the strong showing of this company, which comprises 4.86 percent of the portfolio.

"It did well because it went up," Mr. Gulden told, imparting Yogi Berra-like wisdom.

"Eon Labs [ELAB] was a particularly strong performer during the quarter," Mr. Gulden said, referring to the fund's third largest holding. Eon typifies a strategic move to capitalize on Medicare reform by increasing health care holdings, which is now the sector in with the largest representation in the fund at 28.07 percent. "With Medicare recipients obligated to purchase more and more generic drugs in an effort to keep down prices, generic drug makers like Eon Labs will see growth."

In November 2003, the US Senate approved a plan to overhaul Medicare by infusing $400 billion into the government-sponsored health care system for the elderly.

Mr. Gulden prefers smaller companies filling niches in the health care industry over the large pharmaceutical companies.

Mr. Gulden points out that the US is home to the major pharmaceutical companies and the highest drug prices in the world, which the drug companies consider necessary to fund research and development of new drugs. While Mr. Gulden does not dispute this logic, he points out that this system is unsustainable, as cheaper prices prompt consumers to buy prescription drugs outside US borders. Price controls are therefore inevitable, according to Mr. Gulden, and the major pharmaceutical companies will be hardest hit by this development.

"I'm not focused on the major pharmaceuticals in my portfolio--they are no longer great growth companies," Mr. Gulden said. "They're also political footballs."

"I'm more concerned with companies that will see faster growth in light of the current Medicare reform and the ageing American population," he added.

Smaller health care companies are better positioned to capitalize on growth in health care.

"eResearch [ERES], a company that crosses the border between information technologies and health care, was another strong performer," Mr. Gulden added.

However, this long-term strategy did not result in strong short-term results for all of the Pax World Growth Fund's health care holdings. Caremark (CMX) and ExpressScript (ESRX), two prescription benefit managers, did not post particularly good performance recently. However, the companies are well managed, and have good quality distribution capabilities and record keeping, according to Mr. Gulden.

"These companies are primed to take on the additional pharmaceutical spending created by the Medicare bill," he concluded.


| Reports | SRI Financial Professionals Directory | Tools | News | SRI Performance and Trends | About Us | Contact
© SRI World Group, Inc. - All rights reserved
Terms of use - Privacy Policy - OneReportTM Network